Abstract
Introduction

Alendronate, one of the bisphosphonates, is effective and widely used in the prevention and treatment of glucocorticoid-induced osteoporosis. Postmarketing surveillance of alendronate alerted that alendronate could cause chemical esophagitis, including severe ulcerations in some patients (1). Many of these cases occurred in elderly individuals or in individuals who did not follow the recommended dosing instructions (1)
h a g u s ( P a n e l A, B ) a n d CT s c a n o f t h e c h e s t ( P a n e l C) o n a d mi s s i o n . P a n e l A a n d B s h o w s e v e r e , c i r c u mf e r e n t i a l e r o s i o n s a n d l o n g i t u d i n a l u l c e r a t i o n s i n t h e mi d d l e ( A) a n d d i s t a l ( B ) e s o p h a g u s . P a n e l
C s h o ws c o n c e n t r i c e s o p h a g e a l -wa l l t h i c k e n i n g a n d c i r c u mf e r e n t i a l h i g h -d e n s i t y a r e a a r o u n d t h e e s o p h a g u s s u g g e s t i v e o f t r a n s mu r a l i n f l a mma t i o n a n d i t s e x t e n s i o n t o t h e t i s s u e s a r o u n d t h e e s o p h a g u s .
swallow his own secretions. Endoscopy showed severe, circumferential erosions and longitudinal ulcerations in the middle and distal portion of the esophagus (Fig. 1A, 1B (4, 6) .
Discussion
Injury to the esophageal mucosa caused by tablets passing through the esophagus is a rare but well-known clinical condition known as pill-esophagitis (2). Recent reports have shown that oral bisphosphonates, including alendronate, can cause pill-esophagitis (1, 3-6)-. A large review of worldwide post-marketing surveillance data for alendronate in 1996 showed that 199 (0.04%) reports of esophageal adverse events were received for an estimated 475,000 patients (spontaneous reporting to the manufacturer) (1). On the other hand, in the double-blind placebo-controlled trials for osteoporosis, the overall incidence of adverse upper gastrointestinal effects was similar in patients receiving
On the basis of the analyses of the cases with esophageal adverse events in association with alendronate use in the literature, the postulated pathophysiologic mechanisms of esophagitis associated with alendronate use were direct esophageal irritation with prolonged local mucosal exposure to the drug, and possibly reflux of drug-containing gastric contents (1) . A study using a rabbit model of alendronateinduced esophagitis showed that alendronate stimulates net ion (Na) transport in esophageal epithelium by increasing apical membrane sodium channel activity without overt morphological changes and alteration in barrier function (8) . Also alendronate is far more damaging at acidic than at neu-tral pH (8) (10) . The DLST has a general sensitivity of 60-70% and specificity of 85-100% (10) . Other groups found specificities of 100% repeatedly, for example, in carbamazepine hypersensitivity and lamotrigine hypersensitivity, and of 93% for beta-lactam hypersensitivity as exposed, while nonallergic persons showed no or only very rarely some proliferation to the drug (11, 12) .
In 
